Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy.
van der Straten L, Dinmohamed AG, Westerweel PE, Langerak AW, Riedl J, Doorduijn JK, Kater AP, Levin MD. van der Straten L, et al. Leuk Lymphoma. 2018 Nov;59(11):2757-2761. doi: 10.1080/10428194.2018.1452215. Epub 2018 Apr 4. Leuk Lymphoma. 2018. PMID: 29616852 No abstract available.
Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.
Kater AP, van Oers MHJ, van Norden Y, van der Straten L, Driessen J, Posthuma WFM, Schipperus M, Chamuleau MED, Nijland M, Doorduijn JK, Van Gelder M, Hoogendoorn M, De Croon F, Wittebol S, Kerst JM, Marijt EWA, Raymakers RAP, Schaafsma MR, Dobber JA, Kersting S, Levin MD; HOVON CLL study group. Kater AP, et al. Among authors: van norden y, van oers mhj, van der straten l, van gelder m. Haematologica. 2019 Jan;104(1):147-154. doi: 10.3324/haematol.2018.193854. Epub 2018 Aug 16. Haematologica. 2019. PMID: 30115656 Free PMC article. Clinical Trial.
Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia.
van der Straten L, Kater AP, Doorduijn JK, van den Broek EC, Posthuma EFM, Dinmohamed AG, Levin MD. van der Straten L, et al. Among authors: van den broek ec. Ann Hematol. 2020 May;99(5):1081-1091. doi: 10.1007/s00277-020-03994-8. Epub 2020 Mar 19. Ann Hematol. 2020. PMID: 32193628
Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study.
Saberi Hosnijeh F, van der Straten L, Kater AP, van Oers MHJ, Posthuma WFM, Chamuleau MED, Bellido M, Doorduijn JK, van Gelder M, Hoogendoorn M, de Boer F, Te Raa GD, Kerst JM, Marijt EWA, Raymakers RAP, Koene HR, Schaafsma MR, Dobber JA, Tonino SH, Kersting SS, Langerak AW, Levin MD. Saberi Hosnijeh F, et al. Among authors: van der straten l. Exp Hematol. 2020 Sep;89:55-60.e6. doi: 10.1016/j.exphem.2020.08.002. Epub 2020 Aug 8. Exp Hematol. 2020. PMID: 32781097 Free article. Clinical Trial.
Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.
Raa DGT, van der Straten L, van Gelder M, Kersting S, Levin MD, Mous R, van der Straaten HM, Nijziel MR, van der Spek E, Posthuma EFM, Visser HPJ, van der Klift M, de Heer K, Bellido M, Doorduijn JK, Bruns AHW, Raijmakers RAP, Kater AP; HOVON CLL study group. Raa DGT, et al. Among authors: van der straten l. Leuk Lymphoma. 2022 Oct;63(10):2276-2289. doi: 10.1080/10428194.2022.2084731. Epub 2022 Jun 23. Leuk Lymphoma. 2022. PMID: 35737364
17 results